Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24480416 | 0.79 | HRH3 (0.34) | HRH3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13620647 | 0.79 | ALDH1A1 (0.38) | HRH3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18136207 | 0.79 | HRH3 (0.33) | HRH3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL24185469 | 0.79 | ALDH1A1 (0.30) | — | |
| SCHEMBL25695919 | 0.79 | OPRL1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL21077835 | 0.79 | HRH3 (0.32) | HRH3 | |
| SCHEMBL24185424 | 0.77 | HRH3 (0.34) | HRH3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL22565052 | 0.77 | HRH3 (0.34) | HRH3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18202930 | 0.77 | HRH3 (0.33) | HRH3OPRM1OPRK1OPRL1 | |
| SCHEMBL25937490 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | HRH3 3507/4885OPRM1 4623/4885OPRD1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.